Atomo Diagnostics Share Price and Company Fundamentals
Last traded: Today at 6:10 AM
Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection. The company has operations in Europe, Asia, Africa, and Central and South America. Atomo Diagnostics Limited was founded in 2010 and is headquartered in Leichhardt, Australia.
|Primary activities||The expansion of global sales and continued development of its rapid test device technologies.|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||Level 2 701-703 Parramatta Road Leichhardt NSW 2040 Australia|
|Phone / Fax||61 2 9099 4750 /|
|Share registry||LINK MARKET SERVICES LIMITED|
Atomo Diagnostics does not pay dividends.
As of May 2021, following are the company executives and directors listed on Atomo Diagnostics.
|Mr. John Michael Kelly||Founder, CEO, MD & Director||578.52k|
|Mr. William Edward Souter BCom, LLB (Adel), IPAA||Chief Financial Officer||104.36k|
|Mr. Mark Smith||Chief Operating Officer||234.86k|
|Mr. Fabio Baglioni||Chief Commercial Officer||117.5k|
|Ms. Gillian Maria Nairn||Company Sec.|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Atomo Diagnostics is 108.03M and its enterprise value is 82.79M. The enterprise value to revenue ratio of AT1 is 9.19.
Companies similar to Atomo Diagnostics (AT1)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Atomo Diagnostics (ASX:AT1) Frequently Asked Questions
1. What is Atomo Diagnostics's Stock Symbol?
Atomo Diagnostics trades on ASX under the ticker symbol "AT1".
2. What is Atomo Diagnostics's stock price today?
One share of AT1 stock can currently be purchased for approximately $0.19.
3. How can I contact Atomo Diagnostics?
Atomo Diagnostics's mailing address is Level 2 701-703 Parramatta Road Leichhardt NSW 2040 Australia. The company can be reached via phone at 61 2 9099 4750.
4. What is Atomo Diagnostics's official website?
The official website of Atomo Diagnostics is http://atomodiagnostics.com.
5. Which share registry manages Atomo Diagnostics's stock?
Atomo Diagnostics's stock is managed by LINK MARKET SERVICES LIMITED.